| Literature DB >> 27639599 |
Lijun Meng1, Shaoyan Hu2, Jian Wang2, Shan He1, Yi Zhang3.
Abstract
Dendritic cells (DCs) are critical regulators of adaptive immune responses. DCs can elicit primary T cell responses at low DC:T cell ratios through their expression of high levels of antigen-presenting molecules and costimulatory molecules. DCs are important for induction of functionally diverse T cell subsets such as CD4+ T helper (Th)1 and Th17 cells and effector CD8+ T cells able to reside in epithelial tissues. Recent studies begin illuminating the underlying mechanism by which DCs regulate specialized T cell subsets. DCs are composed of subsets that differ in their phenotype, localization and function. DCs expressing high levels of DLL4 (DLL4+ DCs), which is a member of Notch ligand family, are newly discovered cells that have greater ability than DLL4- DCs to promote the generation of Th1 and Th17 CD4+ T cells. DLL4 derived from DLL4+ DCs is also important for promoting the differentiation and expansion of effector CD8+ T cells. Experimental studies have demonstrated that selective deletion of DLL4 in DCs causes impaired antitumor immunity. In contrast, blocking DLL4 leads to dramatic reduction of inflammatory T cell responses and their-mediated tissue damage. We will discuss emerging functional specialization within the DLL4+ DC compartment, DLL4+ DC biology and the impact of pharmacological modulation of DLL4 to control inflammatory disorders.Entities:
Keywords: Alloimmunity and autoimmunity; DLL4; DLL4(+) DCs; Notch signaling; Tumor immunity
Mesh:
Substances:
Year: 2016 PMID: 27639599 PMCID: PMC5571445 DOI: 10.1016/j.phrs.2016.09.001
Source DB: PubMed Journal: Pharmacol Res ISSN: 1043-6618 Impact factor: 7.658